

THE LAW OFFICES OF
THOMAS C. COOK
ATTORNEY AND COUNSELOR AT LAW
10470 W. CHEYENNE AVE., SUITE 115, PMB 303
LAS VEGAS, NEVADA 89129
(702) 524-9151
tccesq@aol.com

September 22, 2023

OTC Markets Group, Inc.
304 Hudson Street, Second Floor
New York, NY 10013

Re: BioTech Medics, Inc. (BMCS) (the "Issuer")

Gentlemen:

BioTech Medics, Inc., a Wyoming corporation, (the "Issuer"), has requested our opinion with respect to the amended annual filings publicly disclosed by the Issuer and published in the OTC Disclosure and News Service on August 15, 2023, for the period ending December 31, 2022 and published on March 31, 2022 for the period ended December 31, 2021, as well as the quarterly reports published on May 21, 2022 (period ended March 31, 2022), August 16, 2022 (period ended June 30, 2022), June 14, 2023 (period ended September 30, 2022), August 15, 2023 (period ended March 31, 2023) and August 17, 2023 (period ended June 30, 2023). This opinion is solely for the information of the addressee hereof and OTC Markets Group, Inc. is entitled to rely on such letter in determining whether the Issuer has made adequate current public information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933. The undersigned grants OTC Markets Group, Inc. full and complete permission and rights to publish the letter in the OTC Disclosure and News Service for viewing by the public and regulators.

The undersigned is a U.S. resident and was retained by the Issuer for the purpose of rendering this opinion and related matters. We currently serve as general counsel and regular disclosure counsel for the Issuer. This opinion is based on our knowledge of the law and facts as of the date hereof. The undersigned has examined such corporate records and other documents and such questions of laws as deemed appropriate for the purposes of rendering this opinion.

The undersigned was admitted to the Bar in the State of Nevada in 1994, and is authorized to practice in the State of Nevada and in the laws of the United States. The undersigned is permitted to practice before the Securities and Exchange Commission ("SEC") and has not been barred from practice in any of the foregoing jurisdictions in the last five years. Further, the undersigned counsel is not currently, nor has not in the past five years, been the subject of an investigation, hearing, or proceeding by the SEC, the US Commodity Futures Trading Commission (CFTC), the Financial Industry Regulatory Authority (FINRA), or any other federal, state, or foreign regulatory agency.

In rendering the legal opinion contained in this letter, we have reviewed certain documents and information furnished by the Issuer including but not limited to the Issuer's Articles of Incorporation, Bylaws, and minutes of meetings and actions of its Board of Directors and such other documents as we deemed relevant and necessary as a basis for the opinion hereinafter set forth. In such examinations, we have assumed the genuineness of all signatures set forth on each document, the authenticity of all original documents and the conformity to original documents of all copies of such documents as may have been supplied to us during the course of our examination.

For the purposes of rendering this opinion, we have assumed that no person or entity has engaged in fraud or misrepresentation regarding the inducement relating to, or the execution or delivery of, the documents reviewed. Furthermore, we express no opinion as to the validity of any assumptions, form or content of any financial or statistical data contained therein. The terms used in this opinion shall have the meaning ascribed to them in the documents relied upon in rendering our opinion.

Regarding the common stock of the Issuer, par value \$0.001 (the "Securities"), in the opinion of the undersigned, the amended Annual Report for the period ended December 31, 2022, as published on the OTC Disclosure and News Service on August 15, 2023, the annual report published on March 31, 2022 for the period ended December 31, 2021, as well as the quarterly reports published on May 21, 2022 (period ended March 31, 2022), August 16, 2022 (period ended June 30, 2022), June 14, 2023 (period ended September 30, 2022), August 15, 2023 (period ended March 31, 2023) and August 17, 2023 (period ended June 30, 2023) (i) constitute "adequate current public information" concerning the Securities of the Issuer and "is available" within the meaning of Rule 144(c)(2) under the Securities Act of 1933, (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934 (the "Exchange Act"), (iii) complies as to form with the Pink Sheets Guidelines for Providing Adequate Current Public Information, which are located on the Internet at www.otcmarkets.com, and (iv) has been posted in the OTC Disclosure and News Service. Furthermore, after reasonable investigation I have no reason to believe that such information contained an untrue statement of a material fact or omitted to state a material fact in order to make the statements made, in light of the circumstances under which they were made, not misleading.

Anthony K. Miller, Chief Executive Officer of the Issuer, is responsible for the preparation of the unaudited financial statements contained in the Report. The qualifications of Mr. Miller are outlined in his biographical information set forth in the Report.

The Company's transfer agent is Transfer Online, and to the best of my knowledge is registered with the SEC. We have reviewed a copy of the shareholder list prepared by the transfer agent as of December 31, 2022, December 31, 2021 and the current date to confirm that the number of outstanding shares set forth in the Information is correct.

The undersigned has (i) personally met with the Issuer's management and a majority of its directors, including Anthony K. Miller, (ii) reviewed the Information published by the Issuer on the OTC Disclosure and News Service, and (iii) discussed the Information with management and a majority of the directors of the Issuer. To the best of our knowledge, and after reasonable inquiry of the Issuer's management and directors, there is no officer, director, 5% holder, or counsel currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.

The undersigned has not received, nor has any agreement or had any discussions to receive in the future, shares of the Issuer's stock in payment for services.

This opinion is solely for the information of the addressee hereof and the other parties specifically identified in the first paragraph hereof, and is not to be quoted in whole or in part or otherwise referred to, nor is it to be filed with any governmental agency or other person without our prior written consent. Other than the addressee hereof and such other parties, no one is entitled to rely on this opinion. This opinion is based on our knowledge of the law and facts as of the date hereof. We assume no duty to communicate with you with respect to any matter which comes to our attention hereafter.

To the best of the undersigned counsel's knowledge, the Issuer has not been a "shell company" as defined in Rules 405 of the Securities Act of 1933 and 12b-2 of the Exchange Act of 1934.

Thank you for your consideration and attention.

Sincerely,

A handwritten signature in dark ink, appearing to read 'T. C. Cook', followed by a long horizontal line extending to the right.

Thomas C. Cook, Esq.